Suven Life Sciences Limited (SUVEN) AI Stock Analysis

Suven Life Sciences Limited

(NSE:SUVEN)

Select Model

Rating:42Neutral

Price Target:INR 277.00▲(7.32% Upside)

Action:reiterated

Date:10/10/26

The overall score is low, driven primarily by very weak financial performance: multi‑year losses, sharply negative margins and deteriorating, deeply negative operating and free cash flow create significant execution and liquidity risk despite a currently strong, low‑debt balance sheet. Technical indicators add to the cautious view, with the share price trading below all major moving averages, a strongly negative MACD, and oversold RSI and stochastic readings signalling sustained selling pressure and high volatility. Valuation further reinforces the risk profile, as a negative P/E reflects the absence of positive earnings and there is no dividend data to support an income‑based investment case, leaving the stock dependent on a future turnaround that is not yet evident in the reported numbers.

Positive Factors

FY2026 Revenue GrowthThe FY2026 revenue rebound indicates that demand for the company’s offerings can recover after weaker periods. If the improvement is sustained, greater project activity and customer orders could provide a larger base from which operating efficiency and future profitability may develop.

Negative Factors

Persistent UnprofitabilityRecurring operating and net losses show that the current business model is not converting activity into sustainable earnings. Continued unprofitability can restrict internal reinvestment, weaken capital productivity, and make future growth dependent on an eventual improvement in economics or external funding.

Suven Life Sciences Limited (SUVEN) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 64.69B
Dividend Yield: ―
Average Volume (3M): 50.07K
Price to Earnings (P/E): -17.8
Beta (1Y): 1.81
Revenue Growth: 17.26%
EPS Growth: -68.16%
Country: India
Employees: 141
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Suven Life Sciences Limited Business Overview & Revenue Model

Company Description

Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative cond...

How the Company Makes Money

Suven Life Sciences has primarily generated revenue through business-to-business pharma services rather than branded drug sales. Key revenue streams have included: (1) Contract research and development services—fees for medicinal chemistry, process R...

Suven Life Sciences Limited Financial Statement Overview

Summary

Financial performance is very weak: the company has reported persistent and worsening net losses over multiple years, margins have turned sharply negative with net loss nearing 39% of sales and operating losses exceeding 40% of revenue, and cash burn is severe and escalating, with deeply negative operating and free cash flow. The only offsetting positive is a low‑debt balance sheet with rising assets and equity that currently supports solvency, but this capital base is not yet generating returns and is at risk of erosion if losses persist.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	71.15M	71.15M	66.56M	116.93M	135.39M	118.44M
Gross Profit	-294.33M	-419.28M	-276.33M	108.69M	129.74M	-137.31M
EBITDA	-2.71B	-2.71B	-1.55B	-994.18M	-1.11B	-1.17B
Net Income	-2.76B	-2.76B	-1.61B	-1.05B	-1.18B	-1.22B
Balance Sheet
Total Assets	6.24B	6.24B	1.35B	2.85B	3.89B	1.08B
Cash, Cash Equivalents and Short-Term Investments	5.18B	5.18B	600.05M	2.40B	2.31B	504.36M
Total Debt	166.94M	166.94M	0	7.10M	16.05M	32.09M
Total Liabilities	328.14M	328.14M	251.97M	148.62M	135.91M	118.89M
Stockholders Equity	5.91B	5.91B	1.10B	2.70B	3.75B	961.45M
Cash Flow
Free Cash Flow	-1.06B	-3.03B	-1.86B	-1.15B	-1.06B	-1.47B
Operating Cash Flow	-1.03B	-2.98B	-1.48B	-1.15B	-1.03B	-1.28B
Investing Cash Flow	-2.02B	-4.66B	1.49B	944.36M	-2.61B	-222.29M
Financing Cash Flow	3.00B	7.57B	-7.10M	-10.54M	3.96B	1.46B

Suven Life Sciences Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price258.10

Price Trends

50DMA326.55Negative

100DMA317.02Negative

200DMA248.25Positive

Market Momentum

MACD-17.77Positive

RSI29.99Positive

STOCH13.39Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUVEN, the sentiment is Negative. The current price of 258.10 is below the 20-day moving average (MA) of 283.63, below the 50-day MA of 326.55, and above the 200-day MA of 248.25, indicating a neutral trend. The MACD of -17.77 indicates Positive momentum. The RSI at 29.99 is Positive, neither overbought nor oversold. The STOCH value of 13.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SUVEN.

Suven Life Sciences Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:SUVEN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:DIVISLAB	77Outperform	INR 2.58T	88.73	―	0.31%	16.35%	26.84%
IN:NEULANDLAB	66Neutral	INR 252.76B	50.78	―	0.17%	78.33%	182.61%
IN:SPARC	61Neutral	INR 57.41B	3.62	―	―	2855.80%	―
IN:PPLPHARMA	56Neutral	INR 318.26B	-151.42	―	0.06%	9.43%	-767.49%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:LAURUSLABS	54Neutral	INR 1.29T	96.96	―	0.08%	23.03%	95.69%
IN:SUVEN	42Neutral	INR 72.93B	-17.77	―	―	17.26%	-68.16%

* General Sector Average

Performance Comparison

IN:SUVEN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:SUVEN	Suven Life Sciences Limited	258.10	61.10	31.02%
IN:DIVISLAB	Divi's Laboratories Limited	9715.00	2944.08	43.48%
IN:LAURUSLABS	Laurus Labs Ltd.	2392.00	1409.93	143.57%
IN:NEULANDLAB	Neuland Laboratories Ltd.	19701.10	2127.03	12.10%
IN:PPLPHARMA	Piramal Pharma Limited	239.05	38.55	19.23%
IN:SPARC	Sun Pharma Advanced Research Co. Ltd.	176.90	40.10	29.31%

Suven Life Sciences Limited Corporate Events

Suven Life Sciences completes enrollment in global Phase 3 Masupirdine trial for Alzheimer’s agitation

Sep 3, 2026

Suven Life Sciences has completed patient enrollment in its global Phase 3 trial of Masupirdine for agitation associated with Alzheimer’s dementia, exceeding its original target by randomizing 424 patients across sites in the U.S. and Europe. T...

Suven Life Sciences Opens Special Window for Physical Share Transfer Requests

Jul 14, 2026

Suven Life Sciences Limited has published newspaper advertisements in Business Standard and Nava Telangana announcing a special window for re-lodgment of transfer requests for physical share certificates. The move is in compliance with a recent SEBI...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 10, 2026

Suven Life Sciences Limited AI Stock Analysis